Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kailera Therapeutics Inc.
Headquarters: Waltham, MA, United States of America
Website: https://www.kailera.com/
Year Founded: 2024
Status: Private
BioCentury | Mar 3, 2025
Deals
The dealmaking at the heart of the NewCo boom
Formed with Hummingbird assets, $187M, Callio brings trend to Singapore
BioCentury | Feb 12, 2025
Product Development
Promising early data for Tonghua Dongbao’s obesity program
BioCentury’s latest Clinical Report finds the obesity data came in a week when markets failed to reward readouts
BioCentury | Feb 7, 2025
Deals
Under Bain’s ownership, Mitsubishi Tanabe to seek deals, growth in Japan
Japanese pharma’s parent chooses $3.4B buyout to create PE-backed standalone company
BioCentury | Jan 29, 2025
Deals
The NewCo boom signals China’s galloping speed of innovation
Companies founded in the West with Asian assets tell a story of China speed
BioCentury | Jan 28, 2025
Management Tracks
Thomas Barnes named CEO of Averna
Plus: Panetta given emeritus title at Biocom and updates from Kailera, Harness, Nuevocor, Janux, Umoja and more
BioCentury | Jan 18, 2025
Management Tracks
Moves at FDA, NIH
Plus: updates on AZ, Actimed, Kailera, Nasus and more
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
BioCentury | Oct 7, 2024
Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
Items per page:
1 - 10 of 11